Min Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Min Zhao has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Qi Chen
Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
14 shared publications Yunhui Tang
Department of Family Planning The Obstetrics & Gynaecology Hospital of Fudan University Shanghai China
7 shared publicationsXinyi Sun
Department of Obstetrics, Gynaecology and Reproductive Sciences, Faculty of Medical and Health Science, The University of Auckland, Auckland, 1142
6 shared publicationsYongxiang Yin
Department of Pathology, Wuxi Maternity and Child Health Care Hospital, Jiangnan University, Wuxi, China
6 shared publicationsDengxin Zhang
Department of Anaesthesia, Wuxi Maternity and Child Health Care Hospital, Jiangnan University, Wuxi, China
4 shared publicationsLin Wang
Department of Gynaecology, Wuxi Maternity and Child Health Care Hospital, Jiangnan University, Wuxi, China
4 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Surgical Treatment Options and the Subtypes of Cesarean Scar Pregnancy Did Not Affect the Probability of a Subsequent Pregnancy: A Prospective Cohort Study
Background and Aim: Cesarean scar pregnancy (CSP) is rare but poses a potentially life‐threatening complication. There is currently insufficient evidence in the literature regarding the impact of CSP treatment on future fertility due to limited clinical studies on a large scale. Here, we investigated the future reproductive outcomes of women with CSP. Methods: From December 2019 to July 2023, women diagnosed with CSP at the Hospital of Obstetrics and Gynaecology of Fudan University, Shanghai, China, were followed up by telephone calls. Data on future fertility and outcomes were collected. Results: Among 302 women, excluding three who did not answer the question, 234 (77.5%) did not express their intention to conceive in future, while only 65 (22%) expressed an intention to conceive again. Among these 65 women intending to conceive, 14 (21.5%) achieved pregnancy. In contrast, among women who did not intend to conceive, 31 (15.4%) achieved pregnancy. After excluding women within 12 months of treatment, the analysis showed no statistical difference in successful conception between women who intended to conceive again and those who did not ( p = 0.0523). Additionally, among the 45 who achieved pregnancy, 26 resulted in live births. In women with successful conception, there was no statistical difference in the association between CSP treatment or CSP subtype and successful conception ( p = 0.6913 or p = 0.5823). Conclusion: Our study found that 22% of women with CSP intended to conceive, and 29% of our study cohort had a subsequent pregnancy. There was no association between treatment options or CSP subtype and successful conception. Additionally, the incidence of complications in subsequent pregnancies was comparable to that reported in the literature for women without a history of CSP. Our findings suggest that surgical treatments for CSP may not negatively affect future fertility.
- 22 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Open AccessSurgical Treatment Options and the Subtypes of Cesarean Scar Pregnancy Did Not Affect the Probability of a Subsequent Pregnancy: A Prospective Cohort Study
Background and Aim: Cesarean scar pregnancy (CSP) is rare but poses a potentially life‐threatening complication. There is currently insufficient evidence in the literature regarding the impact of CSP treatment on future fertility due to limited clinical studies on a large scale. Here, we investigated the future reproductive outcomes of women with CSP. Methods: From December 2019 to July 2023, women diagnosed with CSP at the Hospital of Obstetrics and Gynaecology of Fudan University, Shanghai, China, were followed up by telephone calls. Data on future fertility and outcomes were collected. Results: Among 302 women, excluding three who did not answer the question, 234 (77.5%) did not express their intention to conceive in future, while only 65 (22%) expressed an intention to conceive again. Among these 65 women intending to conceive, 14 (21.5%) achieved pregnancy. In contrast, among women who did not intend to conceive, 31 (15.4%) achieved pregnancy. After excluding women within 12 months of treatment, the analysis showed no statistical difference in successful conception between women who intended to conceive again and those who did not ( p = 0.0523). Additionally, among the 45 who achieved pregnancy, 26 resulted in live births. In women with successful conception, there was no statistical difference in the association between CSP treatment or CSP subtype and successful conception ( p = 0.6913 or p = 0.5823). Conclusion: Our study found that 22% of women with CSP intended to conceive, and 29% of our study cohort had a subsequent pregnancy. There was no association between treatment options or CSP subtype and successful conception. Additionally, the incidence of complications in subsequent pregnancies was comparable to that reported in the literature for women without a history of CSP. Our findings suggest that surgical treatments for CSP may not negatively affect future fertility.
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 171 (1)
Placenta-derived trophoblast extracellular vesicles contain unique miRNAs that inhibit ovarian cancer cell growth
Previous reports have indicated that placental trophoblast extracellular vesicles (EVs) possess unique properties that enable them significantly to inhibit the proliferation of ovarian cancer cells in vitro and slow ovarian tumour growth in an in vivo model, while EVs derived from monocytes did not. However, the mechanisms underlying the inhibitory effects of trophoblast EVs remain unclear. In this study, we characterized the microRNAs (miRNAs) uniquely present in placental trophoblast EVs but absent from THP-1 monocyte-derived EVs. Through bioinformatic analysis, we elucidated the potential involvement of these unique miRNAs in the negative regulation of proliferation pathways implicated in ovarian cancer. Functional assays demonstrated that placental trophoblast EVs inhibited ovarian cancer cell proliferation, and this effect was reversed upon blocking EV uptake, indicating the transfer of the contents of the EVs as a crucial mechanism modulating cancer cell viability. Using miRNA mimics, we also demonstrated that specific miRNAs from placental trophoblast EVs exhibited inhibitory effects on ovarian cancer cell proliferation, highlighting the potential of placental trophoblast EVs as therapeutic agents. These findings not only shed light on the molecular mechanisms underlying the therapeutic efficacy of placental trophoblast EVs but also provide valuable insights into the potential development of miRNA-based therapies for ovarian cancer, including the use of trophoblast EVs as a therapeutic for ovarian cancer.
- 15 January 2026
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 171 (1)
Open AccessPlacenta-derived trophoblast extracellular vesicles contain unique miRNAs that inhibit ovarian cancer cell growth
Previous reports have indicated that placental trophoblast extracellular vesicles (EVs) possess unique properties that enable them significantly to inhibit the proliferation of ovarian cancer cells in vitro and slow ovarian tumour growth in an in vivo model, while EVs derived from monocytes did not. However, the mechanisms underlying the inhibitory effects of trophoblast EVs remain unclear. In this study, we characterized the microRNAs (miRNAs) uniquely present in placental trophoblast EVs but absent from THP-1 monocyte-derived EVs. Through bioinformatic analysis, we elucidated the potential involvement of these unique miRNAs in the negative regulation of proliferation pathways implicated in ovarian cancer. Functional assays demonstrated that placental trophoblast EVs inhibited ovarian cancer cell proliferation, and this effect was reversed upon blocking EV uptake, indicating the transfer of the contents of the EVs as a crucial mechanism modulating cancer cell viability. Using miRNA mimics, we also demonstrated that specific miRNAs from placental trophoblast EVs exhibited inhibitory effects on ovarian cancer cell proliferation, highlighting the potential of placental trophoblast EVs as therapeutic agents. These findings not only shed light on the molecular mechanisms underlying the therapeutic efficacy of placental trophoblast EVs but also provide valuable insights into the potential development of miRNA-based therapies for ovarian cancer, including the use of trophoblast EVs as a therapeutic for ovarian cancer.
- Open Access
- 15 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Krukenberg tumours: diagnosis challenges, treatment approaches, and survival, sixteen-year experience at a single tertiary women’s hospital
Krukenberg tumours are rare metastatic ovarian tumour that originates primarily from the gastrointestinal tract. This study aimed to describe the diagnosis
- 15 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessKrukenberg tumours: diagnosis challenges, treatment approaches, and survival, sixteen-year experience at a single tertiary women’s hospital
Krukenberg tumours are rare metastatic ovarian tumour that originates primarily from the gastrointestinal tract. This study aimed to describe the diagnosis
- Open Access
- 15 January 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 44
Abnormal fasting glucose levels in the diagnosis of GDM may be associated with adverse pregnancy outcomes
Background Gestational Diabetes Mellitus (GDM) presents significant risks to both maternal and foetal health during pregnancy. Purpose This observational study aimed to investigate the association between clinical parameters and adverse pregnancy outcomes in women with GDM. Methods A cohort of 2174 GDM-diagnosed women was analysed, with 1705 experiencing no adverse outcomes and 469 developing complications such as preeclampsia, large for gestational age (LGA) infants, preterm birth, and shoulder dystocia. Clinical data, including maternal age, glucose levels, gestational age, body mass index (BMI), and treatment methods, were collected and analysed. Results Advanced maternal age, higher parity, increased weekly weight gain, and abnormal fasting glucose levels were associated with adverse pregnancy outcomes in women with GDM. In particular, early onset of GDM, elevated weekly weight gain, and abnormal fasting glucose levels were linked to an increased risk of developing preeclampsia and delivering LGA infants. However, no significant associations were found regarding shoulder dystocia. Furthermore, maternal age and weekly weight gain were identified as risk factors for preterm birth. Conclusion This study shows that in addition to well-known risk factors, abnormal fasting glucose levels are significantly linked to developing adverse pregnancy outcomes in women with GDM. Our data suggested that close monitoring of fasting glucose levels and controlling weight gain may significantly reduce the risk of adverse outcomes in pregnancies complicated by GDM.
- 15 January 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 44
Open AccessAbnormal fasting glucose levels in the diagnosis of GDM may be associated with adverse pregnancy outcomes
Background Gestational Diabetes Mellitus (GDM) presents significant risks to both maternal and foetal health during pregnancy. Purpose This observational study aimed to investigate the association between clinical parameters and adverse pregnancy outcomes in women with GDM. Methods A cohort of 2174 GDM-diagnosed women was analysed, with 1705 experiencing no adverse outcomes and 469 developing complications such as preeclampsia, large for gestational age (LGA) infants, preterm birth, and shoulder dystocia. Clinical data, including maternal age, glucose levels, gestational age, body mass index (BMI), and treatment methods, were collected and analysed. Results Advanced maternal age, higher parity, increased weekly weight gain, and abnormal fasting glucose levels were associated with adverse pregnancy outcomes in women with GDM. In particular, early onset of GDM, elevated weekly weight gain, and abnormal fasting glucose levels were linked to an increased risk of developing preeclampsia and delivering LGA infants. However, no significant associations were found regarding shoulder dystocia. Furthermore, maternal age and weekly weight gain were identified as risk factors for preterm birth. Conclusion This study shows that in addition to well-known risk factors, abnormal fasting glucose levels are significantly linked to developing adverse pregnancy outcomes in women with GDM. Our data suggested that close monitoring of fasting glucose levels and controlling weight gain may significantly reduce the risk of adverse outcomes in pregnancies complicated by GDM.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Obstetrics and Gynecology
- Vol. 2026 (1)
Ovary Preservation for Cervical Clear Cell Adenocarcinoma in an 8‐Year‐Old Girl: A Novel Approach
Cervical clear cell adenocarcinoma is a rare malignancy in adolescents and young girls. Since the prescription of diethylstilbestrol (DES) was banned in 1971, only 11 cases have been reported in girls under 10 years in the literature. However, treatment with ovary preservation has not been reported. Here, we report an 8‐year‐old prepubertal girl without a history of exposure to DES who was diagnosed with cervical clear cell adenocarcinoma. Hysterectomy and unilateral oophorectomy were performed. The remaining ovary was transposed to the left iliac fossa to preserve ovarian function for the future. Additionally, ovarian cortical tissue from the removed ovary was cryopreserved. Chemotherapy, including paclitaxel and carboplatin, was started after surgery for four cycles via an implantable venous access port. Additionally, genetic analysis did not identify any known gene mutations in the tumour tissue.
- 1 January 2026
- Published by Wiley in Case Reports in Obstetrics and Gynecology
- Vol. 2026 (1)
Open AccessOvary Preservation for Cervical Clear Cell Adenocarcinoma in an 8‐Year‐Old Girl: A Novel Approach
Cervical clear cell adenocarcinoma is a rare malignancy in adolescents and young girls. Since the prescription of diethylstilbestrol (DES) was banned in 1971, only 11 cases have been reported in girls under 10 years in the literature. However, treatment with ovary preservation has not been reported. Here, we report an 8‐year‐old prepubertal girl without a history of exposure to DES who was diagnosed with cervical clear cell adenocarcinoma. Hysterectomy and unilateral oophorectomy were performed. The remaining ovary was transposed to the left iliac fossa to preserve ovarian function for the future. Additionally, ovarian cortical tissue from the removed ovary was cryopreserved. Chemotherapy, including paclitaxel and carboplatin, was started after surgery for four cycles via an implantable venous access port. Additionally, genetic analysis did not identify any known gene mutations in the tumour tissue.
- Open Access
- 12 February 2025
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 44 (6) , 1027-1032
Are the Risk Factors for Developing Type 1 and Type 2 Cesarean Scar Pregnancy Different?
Objectives: Cesarean scar pregnancy (CSP) is a life‐threatening complication of pregnancy. Early termination of pregnancy is recommended because of the potential risks of uterine rupture if the pregnancy continues. CSP is clinically divided into type 1 and type 2, based on the site of embryo implantation and grow direction of the gestational sac. The clinical risk and treatment options may vary between these subtypes. Identifying the differences and potential factors impacting the development of each type could contribute to improved clinical management.Methods: This retrospective study included 143 women with type 1 CSP and 200 women with type 2 CSP women, diagnosed between January 2020 and July 2023. The primary objective was to analyze the differences in clinical characteristics between the 2 CSP subtypes.Results: Body mass index, the number of previous CSPs, elective abortions, gravidity, and parity were not significantly different between the 2 subtypes. Similarly, the interval between the last cesarean section and the current CSP was not associated with developing the 2 subtypes. However, women with more than 3 prior cesarean sections had an increased risk of developing type 1 CSP. In contrast, vaginal bleeding before diagnosis was more frequently associated with type 2 CSP.Conclusions: Our study with a large sample size found that despite type 2 CSP involving deeper myometrial invasion, the 2 subtypes share many clinical characteristics. Moreover, the clinical risk factors for distinguishing between type 1 and type 2 CSP are limited. Future research to identify predictors for CSP classification is required.
- 12 February 2025
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 44 (6) , 1027-1032
Open AccessAre the Risk Factors for Developing Type 1 and Type 2 Cesarean Scar Pregnancy Different?
Objectives: Cesarean scar pregnancy (CSP) is a life‐threatening complication of pregnancy. Early termination of pregnancy is recommended because of the potential risks of uterine rupture if the pregnancy continues. CSP is clinically divided into type 1 and type 2, based on the site of embryo implantation and grow direction of the gestational sac. The clinical risk and treatment options may vary between these subtypes. Identifying the differences and potential factors impacting the development of each type could contribute to improved clinical management.Methods: This retrospective study included 143 women with type 1 CSP and 200 women with type 2 CSP women, diagnosed between January 2020 and July 2023. The primary objective was to analyze the differences in clinical characteristics between the 2 CSP subtypes.Results: Body mass index, the number of previous CSPs, elective abortions, gravidity, and parity were not significantly different between the 2 subtypes. Similarly, the interval between the last cesarean section and the current CSP was not associated with developing the 2 subtypes. However, women with more than 3 prior cesarean sections had an increased risk of developing type 1 CSP. In contrast, vaginal bleeding before diagnosis was more frequently associated with type 2 CSP.Conclusions: Our study with a large sample size found that despite type 2 CSP involving deeper myometrial invasion, the 2 subtypes share many clinical characteristics. Moreover, the clinical risk factors for distinguishing between type 1 and type 2 CSP are limited. Future research to identify predictors for CSP classification is required.
- 10 October 2024
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 44 (2) , 231-237
Potential Risk Factors for Developing Cesarean Scar Pregnancy in Women With a History of Cesarean Section
Objectives: Cesarean scar pregnancy (CSP) occurs in 0.2%–0.5% of women with a previous cesarean section globally. Multiple factors influence the development of CSP; however, to date, the critical factors contributing to the development of CSP have not been fully explored due to its relatively low incidence. Moreover, CSP can be clinically categorized into type 1 and type 2 CSP. In this retrospective study with a large sample size, we investigated potential risk factors that could contribute to CSP development.Methods: Two hundred‐one women diagnosed with CSP, either type 1 or type 2 CSP, and 1700 pregnant women with a history of cesarean section but without CSP diagnosis in subsequent pregnancy were included. Gravidity, previous live birth(s), consecutive cesarean section(s), surgical abortion(s), the interval between the pregnancies, and maternal age were compared between the 2 groups.Results: Gravidity, the number of previous live births, the number of previous consecutive cesarean sections, and the number of surgical abortions were significantly associated with CSP development in women with a past cesarean section. This association was regardless of the subtypes of CSP. Notably, the interval between 2 pregnancies was also significantly associated with CSP development, but this association was only seen in type 2 CSP. However, maternal age was not an independent risk factor for CSP development. Additionally, a higher incidence of CSP was observed in China compared to that reported in the literature.Conclusion: In addition to a previous cesarean section, our study highlights at the number of surgical abortions also contributes to the development of CSP.
- 10 October 2024
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 44 (2) , 231-237
Potential Risk Factors for Developing Cesarean Scar Pregnancy in Women With a History of Cesarean Section
Objectives: Cesarean scar pregnancy (CSP) occurs in 0.2%–0.5% of women with a previous cesarean section globally. Multiple factors influence the development of CSP; however, to date, the critical factors contributing to the development of CSP have not been fully explored due to its relatively low incidence. Moreover, CSP can be clinically categorized into type 1 and type 2 CSP. In this retrospective study with a large sample size, we investigated potential risk factors that could contribute to CSP development.Methods: Two hundred‐one women diagnosed with CSP, either type 1 or type 2 CSP, and 1700 pregnant women with a history of cesarean section but without CSP diagnosis in subsequent pregnancy were included. Gravidity, previous live birth(s), consecutive cesarean section(s), surgical abortion(s), the interval between the pregnancies, and maternal age were compared between the 2 groups.Results: Gravidity, the number of previous live births, the number of previous consecutive cesarean sections, and the number of surgical abortions were significantly associated with CSP development in women with a past cesarean section. This association was regardless of the subtypes of CSP. Notably, the interval between 2 pregnancies was also significantly associated with CSP development, but this association was only seen in type 2 CSP. However, maternal age was not an independent risk factor for CSP development. Additionally, a higher incidence of CSP was observed in China compared to that reported in the literature.Conclusion: In addition to a previous cesarean section, our study highlights at the number of surgical abortions also contributes to the development of CSP.
- 6 October 2023
- Published by Springer Nature in Human Cell
- Vol. 37 (1) , 285-296
Therapeutic potential of miRNAs in placental extracellular vesicles in ovarian and endometrial cancer
There is a cross-link between the placenta and cancer development, as the placenta is grown as a highly invasive tumour-like organ. However, placental development is strictly controlled. Although the underlying mechanism of this control is largely unknown, it is now well-recognised that extracellular vesicles (EVs) released from the placenta play an important role in controlling placenta proliferation and invasion, as placental EVs have shown their effect on regulating maternal adaptation. Better understanding the tumour-like mechanism of the placenta could help to develop a therapeutic potential in cancers. In this study, by RNA sequencing of placental EVs, 20 highly expressed microRNAs (miRNAs) in placental EVs were selected and analysed for their functions on ovarian and endometrial cancer. There were up to seven enriched miRNAs, including miRNA-199a-3p, miRNA-143-3p, and miRNA-519a-5p in placental EVs showing effects on the inhibition of ovarian and endometrial cancer cell proliferation and migration, and promotion of cancer cell death, reported in the literature. Most of these miRNAs have been reported to be downregulated in ovarian and endometrial cancer. Transfection of ovarian and endometrial cancer cells with mimics of miRNA-199a-3p, miRNA-143-3p, and miRNA-519a-5p significantly reduced the cell viability. Our findings could provide strategies for using these naturally occurring miRNAs to develop a novel method to treat ovarian and endometrial cancer in the future.
- 6 October 2023
- Published by Springer Nature in Human Cell
- Vol. 37 (1) , 285-296
Therapeutic potential of miRNAs in placental extracellular vesicles in ovarian and endometrial cancer
There is a cross-link between the placenta and cancer development, as the placenta is grown as a highly invasive tumour-like organ. However, placental development is strictly controlled. Although the underlying mechanism of this control is largely unknown, it is now well-recognised that extracellular vesicles (EVs) released from the placenta play an important role in controlling placenta proliferation and invasion, as placental EVs have shown their effect on regulating maternal adaptation. Better understanding the tumour-like mechanism of the placenta could help to develop a therapeutic potential in cancers. In this study, by RNA sequencing of placental EVs, 20 highly expressed microRNAs (miRNAs) in placental EVs were selected and analysed for their functions on ovarian and endometrial cancer. There were up to seven enriched miRNAs, including miRNA-199a-3p, miRNA-143-3p, and miRNA-519a-5p in placental EVs showing effects on the inhibition of ovarian and endometrial cancer cell proliferation and migration, and promotion of cancer cell death, reported in the literature. Most of these miRNAs have been reported to be downregulated in ovarian and endometrial cancer. Transfection of ovarian and endometrial cancer cells with mimics of miRNA-199a-3p, miRNA-143-3p, and miRNA-519a-5p significantly reduced the cell viability. Our findings could provide strategies for using these naturally occurring miRNAs to develop a novel method to treat ovarian and endometrial cancer in the future.